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ABSTRACT: Recombinant llama heavy-chain antibody fragments
(VHHs) are promising tools in the ﬁeld of targeted nanomedicine.
7D12, a VHH against the epidermal growth factor receptor (EGFR)
that is overexpressed in various cancers, has been evaluated as an
eﬀective cancer-targeting VHH in multiple studies. The small size of
VHHs (15−20 kDa) results in a low circulation half-life, which can be
disadvantageous for certain applications. A solution to this problem is
to attach VHHs to the surface of nanoparticles to increase the
hydrodynamic radius of the conjugate. This approach simultaneously
allows the incorporation of diﬀerent VHHs and other targeting
moieties and therapeutic components into one structure, creating
multispeciﬁcity and versatility for therapy and diagnosis. Here, we
present the construction of highly deﬁned 7D12-containing nanoparticles by utilizing thermoresponsive diblock elastin-like
peptides that reversibly self-assemble into micellar structures. The resulting particles have a hydrodynamic radius of 24.3 ± 0.9
nm and retain full EGFR-binding capacity. We present proof of concept of the usability of such particles by controlled
incorporation of a photosensitizer and show that the resulting nanoparticles induce EGFR-speciﬁc light-induced cell killing. This
approach is easily extended to the controlled incorporation of various functional modules, improving therapy and diagnosis with
targeted nanomedicine.
■ INTRODUCTION
The variable region of heavy-chain antibodies found in
cameloids, called VHH, is of great interest to the ﬁeld of
nanomedicine.1−3 VHHs are thermo- and pH-stable proteins
that are well tolerated by the human immune system. Their
aﬃnity can equal or even supersede that of “conventional”
antibodies. In combination with cytotoxic agents, tumor-
targeting VHHs can speciﬁcally recognize and kill cancer
cells.4,5 Although their small size of 15−20 kDa allows deeper
tissue penetration than conventional antibodies, it also results
in a low circulation half-life.
Nanoparticles decorated with VHHs have been developed to
overcome the short blood-circulation time by increasing the
hydrodynamic radius; the nanoparticle structure furthermore
enables increased and more versatile drug loading.6−8
Decoration with VHHs usually follows particle formation,
and encapsulation or attachment of a desired payload is
typically achieved during particle formation or via an additional
coupling step. This procedure makes it diﬃcult to precisely
assess and reproducibly control the resulting VHH concen-
tration on the particles’ surface and the VHH-to-payload ratios.
Controlling these parameters is essential to achieve maximum
eﬃcacy with minimal side eﬀects. Thus, there is a clear need for
optimally deﬁned and controlled VHH-displaying nano-
particles.
Elastin-like peptides (ELPs) are biocompatible polypeptides
that form amorphous coacervates in a temperature-dependent
fashion.9−11 They are composed of repeating pentameric units
with the sequence glycine-X-glycine-valine-proline (GXGVP),
where X can be any amino acid.11,12 ELPs reversibly transform
from a soluble, disordered state below the transition temper-
ature to an assembled state consisting of type-II β-turns, type-I
β-turns, and β-strands above the transition temperature.13−16
This behavior is thermodynamically driven: at the transition
temperature, solvation of the protein backbone becomes
entropically unfavorable. The conformational change and
exposure of hydrophobic residues followed by assembly results
in liberated water molecules, lowering the total energy of the
system. Further increases in temperature enhance this eﬀect.
This so-called lower critical solution temperature (LCST)
highly depends on the nature of the guest residue X, with
hydrophilic residues raising the LCST and hydrophobic
residues lowering it. ELP length, concentration, and presence
of salts also aﬀect the LCST.17
VHH-ELP fusion proteins have previously been synthesized
with the aim to allow easy puriﬁcation via temperature cycling,
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followed by VHH cleavage via introduced protease-sensitive
tags.18 ELP-based nanoparticles have been prepared out of
amphiphilic block copolymers, either by employing ELP
diblock polypeptides with diﬀerent guest residues and, hence,
diﬀerent LCSTs9,10,19 or by coupling ELPs with low LCST to
hydrophilic polymers such as poly(ethylene glycol).20 Given
the excellent biocompatible properties of ELPs,21,22 we
envisioned the possibility of integrating VHH-ELP expression
systems with the nanoparticle-forming potential of ELPs.
Here we report the use of an ELP diblock polypeptide
(ELPDB) to create self-assembling theranostic VHH-nano-
particles. The ELPDB was composed of a “hydrophilic” and a
“hydrophobic” block, terms that relate to the solvation state of
the ELP block at physiological conditions. The hydrophilic
block consisted of 60 pentamers with alanine or glycine guest
residues in a ratio of 3:2 (see SI). The hydrophobic block
contained 60 pentamers with isoleucine as guest residues. We
used the VHH 7D12 that targets the epidermal growth factor
receptor (EGFR).23,24 Fc5, an unrelated VHH directed against
the endothelial receptor Cdc50A, was used as control.25 Well-
deﬁned composite nanoparticles were reproducibly made by
combining 7D12-ELPDB or Fc5-ELPDB fusion proteins with
ELPDB as molecularly dissolved species at predetermined ratios,
followed by heating the solution above the LCST of the
hydrophobic block (Figure 1). The 7D12-decorated ELP
micelles were able to selectively target tumor cells that
(over)express EGFR. Upon incorporation of a third ELPDB to
which the photosensitizer IRDye700DX was conjugated, the
composite nanoparticles could be used for highly eﬀective and
speciﬁc photoimmunotherapy (PIT).
■ MATERIALS AND METHODS
All chemicals and consumables were obtained by Sigma-Aldrich, unless
speciﬁed otherwise.
Cloning and Protein Expression. The VHHs 7D12 and Fc5
were used in this study; 7D12 is directed against EGFR, and Fc5
targets the luminal brain endothelial cell protein Cdc50A.26 7D12 and
Fc5 were expressed as fusion products with ELPDB and 7D12-C-
LPETG-HIS-VSV, hereafter, 7D12, was produced as a control for the
in vitro studies. The gene sequences encoding for ELPDB, pelB-Fc5-
ELPDB and pelB-7D12-ELPDB were cloned into pET-24a(+)
(Novagen) expression vectors,27 by recursive directional ligation,2
transformed into E. coli BLR(DE3) cells and grown on agar plates
containing 30 μg/mL kanamycin overnight at 37 °C. A single colony
was grown overnight at 30 °C, 250 rpm in LB medium containing 50
μg/mL kanamycin and 0.5% w/v D-glucose. The overnight culture was
diluted to an OD600 of 0.1 in ﬁlter-sterilized AIM TB medium
(Formedium) containing 6 g/L glycerol, 0.005% antifoam 204, and 50
μg/mL kanamycin. Cells were grown at 300 rpm at 37 °C for 20 h. For
7D12-ELPDB and Fc5-ELPDB, the culture was shifted to 30 °C after 4 h
of growth.
The pHENIX-7D12-C-LPETG-HIS-VSV plasmid was transformed
in E. coli strain ER2566. Cells were grown at 37 °C in 2xTY medium
containing 3.5% (w/v) glycerol and 50 μg/mL ampicillin until an
OD600 of 0.6−0.8. Protein expression was induced with 1.0 mM
isopropyl β-D-thiogalactoside (IPTG, Serva, Heidelberg, Germany) at
30 °C for 2.5 h.
Protein Extraction and Puriﬁcation. Cells were collected by
centrifugation at 2000 g, 4 °C for 30 min. For cytoplasmic extraction, 1
g of wet cell pellet was resuspended in 2 mL of lysis buﬀer (50 mM
Tris-HCl pH 8.0, 25 mM NaCl, 1 mM EDTA, 0.1 mM PMSF,
Complete Protease Inhibitor Cocktail, 0.5 mg/mL lysozyme) and
incubated for 4 h at 4 °C. Lysis was followed by sonication on a
Branson Soniﬁer 250 (power level 2−4, 12 cycles of 10 s sonication,
10 s breaks). Cell debris was collected by centrifugation at 15,000 g at
4 °C for 15 min. Residual DNA was precipitated by adding 0.5% w/v
poly(ethylene imine) and removed by centrifugation at 15000 g at 4
°C for 15 min. ELPDB was precipitated by adding a saturated solution
of (NH4)2SO4 up to 10−25 v/v%. Proteins were collected by
centrifugation at 15,000 g at 4 °C for 15 min. The pellet was
resuspended in phosphate buﬀered saline and centrifuged to remove
insoluble contaminants at 15000 g at 4 °C for 20 min. This cycle was
repeated until suﬃcient purity was achieved, usually after 2−4 cycles.
ELPs were resuspended in Milli-Q, desalted on a HiPrep 26/10 (GE
Healthcare Life Sciences) with an AKTA Explorer 10 (GE Healthcare
Life Sciences) at 1 mL/min Milli-Q. Residual salt concentration was
below 0.001 mg/mL, as determined by conductivity. The ELP solution
was ﬁlter-sterilized with 0.22 μm PES syringe ﬁlters (Nalgene) and
freeze-dried. Yield was determined by weighing and varied around 43
mg/L culture (Table 1).
For periplasmic extraction of 7D12, 7D12-ELPDB, and Fc5-ELPDB, 1
g of wet cell pellet was resuspended in 10 mL of extraction buﬀer A
(0.2 M TRIS pH 8.0, 0.5 mM EDTA, 20 w/v% sucrose, 0.1 mM
PMSF, Complete Protease Inhibitor Cocktail) and incubated for 30
min at 4 °C. Cells were pelleted by centrifugation at 2000 g for 30 min
Figure 1. Schematic representation of photodynamic therapy with self-
assembling recombinant Llama heavy-chain antibody fragments
(VHHs). Amphiphilic diblock elastin-like polypeptides (ELPDB) are
mixed at low temperatures with ELPDB functionalized with a
photosensitizer and ELPDB functionalized with a VHH directed
against epidermal growth factor receptor (EGFR) at a known ratio.
Upon heating to 37 °C, components spontaneously assemble into
supramolecular structures, simultaneously displaying VHHs and
photosensitizer. Only EGFR expressing cells die after incubation
with particles and subsequent illumination.
Table 1. Overview of Proteins Used in This Study
construct
yielda
(mg/L)
theoretical
massb (Da)
found massc
(Da)
labeling
eﬃciencyd
(%)
ELPDB 43 48198 48198 NA
7D12-ELPDB 33 63049 63031 and
63049
NA
Fc5-ELPDB 47 61903 61904 NA
Alexa647-ELPDB NA 49037 49036 61 ± 2
PS-ELPDB NA 49951 49951 quantitative
7D12FL-ELPDB NA 63475 63457 and
63475
89 ± 12
Fc5FL-ELPDB NA 62330 62332 88 ± 3
aYield speciﬁes obtained product per liter of bacterial culture. bThe
theoretical mass was determined with ExPASy (http://www.expasy.
org/), excluding the N-terminal methionine for ELPDB or the pelB
sequence for 7D12-ELPDB and Fc5-ELPDB (see SI). cMass found after
deconvolution of mass spectrum. dPercentage of labeled protein.
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at 4 °C and the supernatant collected. The extraction was repeated
with extraction buﬀer B (0.2 M Tris pH 8.0, 15 mM MgSO4,
Complete Protease Inhibitor Cocktail). Both supernatants were
pooled before further processing. ELPs were precipitated as described
above. Yield was determined by integration of the absorbance at 280
nm after separation with a Bio-Sec 5 300 Å column on an Agilent Bio-
Inert HPLC with a ﬂow rate of 1 mL/min PBS (Table 1). Aliquots
were ﬂash-frozen in liquid nitrogen and stored at −80 °C. 7D12 was
puriﬁed using Ni-NTA sepharose (IBA, Goettingen, Germany) by
incubating the extraction supernatant with pre-equilibrated Ni-NTA
sepharose for 1 h at 4 °C, and after washing, the proteins were eluted
with 500 mM imidazole. The eluate was dialyzed against 50 mM Tris-
HCl pH 7.5 and 150 mM NaCl.
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
(SDS-PAGE). Proteins were run under reducing conditions on 12%
SDS-PAGE gels. Gels were either silver-stained in the case of ELPDB or
stained with coomassie brilliant blue (CBB) in the case of 7D12,
7D12-ELPDB, and Fc5-ELPDB. Purity was calculated from integrated
pixel intensity after scanning the gels with ImageJ (https://imagej.nih.
gov/ij/).
Electrospray Ionization−Time-of-Flight Mass Spectrometry
(ESI-TOF). Mass was determined by ESI-TOF on a JEOL AccuTOF.
Freeze-dried samples were resuspended in Milli-Q to a concentration
of 10 μM, samples containing buﬀer were ﬁrst desalted with Milli-Q
using Amicon Ultra-0.5 spin ﬁlter units (Millipore, 10 kDa MWCO).
All samples were acidiﬁed with 0.1% formic acid upon injection.
Deconvoluted spectra were obtained using MagTran 1.03 b2.
Size-Exclusion Chromatography Followed by Multiangle
Light Scattering (SEC-MALS). For SEC-MALS, the samples were
separated on a Bio-Sec 5 1000 Å column (Agilent) at 0.4 mL/min; the
mobile phase was 0.1 M phosphate buﬀer pH 7.0 at 35 °C. 7D12-
ELPDB and Fc5-ELPDB were reduced with TCEP to avoid dimer
formation prior to injection for 20 min at 4 °C. Samples were
equilibrated at 35 °C before injection of 20 μL. Light scattering data
were collected on a DAWN HELEOS II MALS detector (Wyatt) and
diﬀerential refractive index was measured on an Optilab T-rex
refractometer (Wyatt). Dn/dc values were determined theoretically.28
Alexa647-ELPDB and PS-ELPDB. Freeze-dried ELPs were
resuspended in 50 mM NaHCO3 pH 7.84. Alexa647-NHS ester and
IRDye 700DX-NHS ester were resuspended in DMSO and added
dropwise to the protein solution. The molar ratio ELPDB to NHS ester
was 1:1 in the case of Alexa 647 and 1:1.3 in the case of IRDye 700DX.
The reaction was allowed to proceed for 4 h at 21 °C, 300 rpm.
Unreacted dye was removed by dialysis against Milli-Q using Amicon
Ultra-0.5 spin ﬁlter units (Millipore, 10 kDa MWCO). The volume of
the dialyzed protein samples was determined; eﬃciency of conjugation
was determined by measuring dye concentration and weighing protein
samples after freeze-drying. Concentrations of the dyes were
determined at 650 nm (ε = 270000 cm−1 M−1) and at 689 nm (ε =
165000 cm−1 M−1) for Alexa647 and IRDye700 DX, respectively. Mass
was determined by ESI TOF (Table 1).
7D12FL and 7D12PS. Fluorescein-5-maleimide and maleimide-
PEG4-DBCO (Jena Bioscience, Jena, Germany) were conjugated to
7D12. The free thiol of the C-terminal cysteine in 7D12 was reduced
by incubation with 20 mM TCEP for 15 min at RT. TCEP was
removed by dialysis to 20 mM phosphate buﬀer pH 7.0, 150 mM
NaCl, and 5 mM EDTA in a 10 kDa MWCO centrifugal unit
(Amicon, Millipore, Billerica, MS, U.S.A.). The VHH was incubated
with either maleimide-5-ﬂuorescein or maleimide-PEG4-DBCO in a
1:3 molar ratio for 2 h at RT. Excess of maleimide probes was removed
by dialysis to 50 mM Tris-HCl pH 7.5 and 150 mM NaCl in a 10 kDa
MWCO centrifugal ﬁlter unit. IRDye700DX-NHS ester (LI-COR,
Lincoln, NE, U.S.A.) was incubated with H2N-PEG3-N3 (Jena
Bioscience, Jena, Germany) in a 3:1 molar ratio for 7 h in 100 mM
phosphate pH 8.6 and 150 mM NaCl. Subsequently, 7D12DBCO was
incubated with PS-N3 in a 1:2 molar ratio o/n at RT. 7D12
PS was
puriﬁed by ﬁlter centrifugation in a 10 kDa MWCO ﬁlter unit using 50
mM Tris-HCl pH 7.5 and 150 mM NaCl. Protein purity was analyzed
with SDS-PAGE gel electrophoresis, and concentration was
determined by measuring ultraviolet absorbance at 495 or 689 nm
for FL and PS conjugates, respectively. Aliquots were stored at −80
°C.
7D12FL-ELPDB and Fc5FL-ELPDB. 7D12-ELPDB and Fc5-ELPDB
were dialyzed to 0.1 M phosphate buﬀer pH 7.0. TCEP was added
in a ratio of 20:1 to reduce the introduced cysteine. Fluorescein-5-
maleimide was dissolved in DMSO and added to 7D12-ELPDB at a
ratio of 10:1. Unbound ﬂuorescein-5-maleimide was removed by
dialysis using Amicon Ultra-0.5 spin ﬁlter units (Millipore, 10 kDa
MWCO). Labeling eﬃciency and protein concentration were
determined by integration of the absorbance at 280 and 495 nm
after separation with a Bio-Sec 5 300 Å column on an Agilent Bio-Inert
HPLC with a ﬂow rate of 1 mL/min 0.1 M NH4HCO3 pH 8.62 (Table
1). Mass was determined by ESI TOF. 7D12FL-ELPDB and Fc5FL-
ELPDB were ﬂash-frozen in liquid nitrogen and stored at −80C. See
Figure S1 for a ﬂuorescent SDS PAGE analysis.
Dynamic Light Scattering and Stability of ELP Particles in
Human Serum. Samples were diluted to a ﬁnal concentration of 2
μM in PBS. Measurements were performed on a Malvern Zetasizer
Nano. Samples were incubated for 5 min at 37 °C before data
collection. Reported values are averages of three independent
measurements. For particle stability, 10 μM of 2% 7D12FL-ELPDB,
98% PS-ELPDB was added to human serum. Human serum alone, to
which an equal volume of PBS alone was added, was taken as control.
Light scattering data was collected at 4 and 37 °C. Aggregation was
inspected visually. Reported values are averages of three independent
measurements.
Cell Culture. Human epidermoid carcinoma A431 cells with
ampliﬁcation of EGFR and high grade astrocytoma E98 cells without
EGFR expression were cultured in DMEM (Lonza, Basel, Switzer-
land), supplemented with 10% FCS (Gibco) and 40 μg/mL
gentamycin (Centrafarm, Etten-Leur, The Netherlands). Cells were
cultured at 37 °C in 5% CO2 in a humidiﬁed atmosphere.
Flow Cytometry. To determine functionality of 7D12FL-ELPDB
monomers, binding to A431 and E98 cells was determined under
noninternalizing conditions at 4 °C. A431 and E98 cells were
dissociated from culture ﬂasks using 10 mM EDTA in PBS and
transferred to V-bottom shaped 96-well microplates (BD Biosciences,
Franklin Lakes, NJ, U.S.A.) at 5 × 105 cells per well. Cells were
blocked with PBA (PBS, 0.5% BSA and 2% FCS) for 10 min at 4 °C,
after which they were incubated with 1 μM 7D12FL-ELPDB or controls
Fc5FL-ELPDB and 7D12FL in PBA for 30 min at 4 °C. After washing
twice with cold PBA, cell-associated ﬂuorescence was quantiﬁed on the
Cyan ﬂow cytometer (Beckman Coulter, Fullerton, CA, U.S.A.) with
parameter FL-1. To determine uptake of VHH functionalized ELP
nanoparticles and compare this to monomeric VHHs, A431 and E98
cells were grown to 80% conﬂuency in 8-well chambered Lab-Tek
chambers (NUNC) after which cells were incubated with a
concentration range of prewarmed 7D12FL; 10% 7D12FL-ELPDB, 5%
Alexa647-ELPDB, 85% ELPDB particles or 10% Fc5FL-ELPDB, 5%
Alexa647-ELPDB, 85% ELPDB particles in DMEM with 10% FCS for 30
min at 37 °C. Cells were washed twice with warm DMEM with 10%
FCS, dissociated with trypsin and taken up in PBA, and cell associated
ﬂuorescence was quantiﬁed on the Cyan ﬂow cytometer with
parameters FL-1 and FL-8. Experiments were performed in triplicate
and statistical signiﬁcance was tested with an unpaired Student’s t test.
Furthermore, cells were imaged after incubation with ELPDB particles
(or equimolar VHH of 7D12FL) on the EVOS microscope using LED
cubes GFP (Fluorescein) and Cy5 (Alexa647).
In Vitro PDT Assays. A431 and E98 cells were cultured in clear 96
wells plates until 80% conﬂuency. Then cells were incubated with a
concentration range of prewarmed 7D12PS or 2% 7D12FL-ELPDB, 98%
PS-ELPDB particles or 2% Fc5FL-ELPDB, 98% PS-ELPDB particles in
DMEM with 10% FCS for 30 min at 37 °C. Cells were washed twice
with warm DMEM with 10% FCS, and subsequently, cells were
illuminated with 100 mW/cm2 for 600 s, reaching a total light dose of
60 J/m2, using a standardized light emitting diode device (690 ± 10
nm). Cells were incubated with 729 nM of 10% 7D12-ELPDB, 10% PS-
ELPDB, 10% Fc5-ELPDB, 10% PS-ELPDB particles, or 72.9 nM 7D12PS
without subsequent illumination to determine dark toxicity. Cell
viability was quantiﬁed using sulforhodamine B (SRB) colorimetric
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assays, and results were expressed as cell viability relative to untreated
illuminated cells.
To examine selectivity of PDT-induced cytotoxicity, 5 × 105 cells
were labeled with DiO (A431) or DID (E98) dye (Life Technologies,
Thermo Fisher Scientiﬁc, Waltham, MA, U.S.A.) according to
manufacturers’ protocol. A431, E98, or 1:1 mixtures of the cells
were plated and subjected to PIT with 30 nM of the particles or
equimolar VHH concentrations of the 7D12PS control as described
above. Four hours after illumination, cells were incubated with 1 μg/
mL propidium iodide (Thermo Fisher Scientiﬁc, Waltham, MA,
U.S.A.) in PBS for 15 min. Cells were visualized with the EVOS
microscope using the RFP channel (propidium iodide), the GFP
channel (DiO-labeled cells), and the Cy5 channel (DiD-labeled cells).
Stability of ELPDB Particles in Human Serum. Stability of
ELPDB particles in serum was evaluated further by incubating 96 nM
[ELP] 2% 7D12FL-ELPDB, 98% PS-ELPDB or 2% Fc5FL-ELPDB, 98%
PS-ELPDB in freshly obtained human serum (HS) for either 30 min, 2
h, or 4 h at 37 °C. Subsequently, the 96 nM stocks were diluted in
DMEM with 10% FCS, and PDT assays were performed with A431
cells as described earlier. Cell viability was compared to controls
incubated with diluted serum without PS-ELPDB micelles and with PS-
ELPDB micelles directly diluted in DMEM with 10% FCS.
■ RESULTS AND DISCUSSION
VHH-ELPDBs were prepared by cloning cDNA sequences
coding for 7D12 and Fc5 in frame with ELPDB. An intervening
cysteine residue was introduced as a handle for maleimide-
based modiﬁcation. Fusion proteins were successfully expressed
in BLR(DE3) Escherichia coli cells by autoinduction (Figure 2).
The sequences were preceded by a pelB leader sequence to
direct the protein to the periplasm of E. coli. The slightly
oxidative milieu in the bacterial periplasm allowed the proper
formation of internal disulﬁde bonds present in 7D12 and Fc5.
The proteins were puriﬁed by inverse-transition cycling. ELPDB
and VHH-ELPDB fusion proteins were obtained in >95% purity
with 20−50 mg/L yield (Table 1, Figure 2A). Molecular masses
of the protein samples were measured via electrospray
ionization time-of-ﬂight spectrometry (ESI-ToF) and agreed
well with the predicted masses (Figure 2B). The N-terminal
formyl methionine of ELPDB was cleaved oﬀ as expected.29 For
7D12-ELPDB and Fc5-ELPDB, complete removal of the pelB
sequence was observed. For 7D12-ELPDB, an additional peak
was found. 7D12 contains an N-terminal glutamine, which is
known to be converted in an autocatalytic or enzymatic step to
Figure 2. Characterization of expressed proteins and formed nanoparticles: (A) SDS-PAGE of ELPDB (silver-stained, absence of aromatic amino
acids in the ELP prevents Coomassie Brilliant Blue (CBB) staining), 7D12-ELPDB, and Fc5-ELPDB (stained with CBB). (B) Mass spectra and
deconvoluted masses of (a) ELPDB, (b) 7D12-ELPDB, and (c) Fc5-ELPDB. (C) Size-exclusion chromatography coupled to multiangle light scattering
of nanoparticles containing 10% 7D12-ELPDB. (D) Evaluation of nanoparticle stability as a function of the fraction of 7D12-ELPDB or Fc5-ELPDB. X-
axis represents the ratio of VHH-ELPDB to ELPDB in the micelles.
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pyroglutamate, resulting in the loss of ammonia, explaining the
18 Da diﬀerence.30 Fc5-ELPDB, which does not contain N-
terminal glutamine, did not show this side product (Table 1).
ELPDB nanoparticles were stable between 25 and 55 °C
(Figure S2). For characterization, puriﬁed ELPDB was heated to
37 °C after which hydrodynamic radius, radius of gyration, and
molecular weight were determined by size-exclusion chroma-
tography, followed by multiangle light scattering (Figures 2C
and S3). The hydrodynamic radius was approximately 24 nm
(Table 2). The ratio of radius of gyration to hydrodynamic
radius, an indication of the morphology of particles, was close
to the theoretical value of a homogeneous sphere (0.778).31,32
The mass distribution (with an average of 10.3 MDa) revealed
that particles consisted of on average 214 monomers per
micelle, in agreement with comparable ELP particles.11
Table 2. Results from SEC-MALS Measurements of the Diﬀerent Nanoparticle Formulations
sample Rh
a (nm) Rrms
b (nm) ρc massd (kDa) monomers per micellee
ELPDB 24.0 ± 0.5 17.2 ± 0.1 0.72 ± 0.02 10300 ± 15 214
10% 7D12-ELPDB 24.6 ± 0.6 17.4 ± 0.1 0.71 ± 0.02 9958 ± 17 200
10% Fc5-ELPDB 24.3 ± 0.6 19.8 ± 0.3 0.81 ± 0.02 10470 ± 16 211
aHydrodynamic radius. bRadius of gyration. cRadius of gyration divided by the hydrodynamic radius. dAverage molecular mass. eMonomers per
micelle calculated with the weighted average molecular mass of ELPDB particles and monomers. See Figure S3 for SEC-MALS data.
Figure 3. Cellular binding and uptake of VHHFL-ELPDB monomers and micelles, respectively. (A) Cell-associated FL ﬂuorescence as determined
with ﬂow cytometry after cold (4 °C) incubation with 1 μM 7D12FL, 7D12FL-ELPDB, or Fc5FL-ELPDB monomers. (B) Cell-associated FL and
Alexa647 ﬂuorescence, as determined with ﬂow cytometry after warm (37 °C) incubation with 10 μM (refers to total ELPDB concentration) of
7D12FL-Alexa647-ELPDB micelles or Fc5FL-Alexa647-ELPDB micelles. Note that there is some unexplained nonspeciﬁc background binding of Alexa-
ELPDB, but not of VHHFL-ELPDB. (C) Cell-associated FL and Alexa647 ﬂuorescence as determined with ﬂow cytometry after warm (37 °C)
incubation of A431 cells with a concentration range of 7D12FL-Alexa647-ELPDB micelles or Fc5FL-Alexa647-ELPDB micelles. * indicates signiﬁcance
with p < 0.05, ** indicates signiﬁcance with p < 0.01, *** indicates signiﬁcance with p < 0.001.
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In order to determine the maximum possible functionaliza-
tion degree of the nanoparticles with VHH, we proceeded by
systematically mixing ELPDB with diﬀerent percentages of
7D12-ELPDB or Fc5-ELPDB. We observed a transition point at
Figure 4. Phototoxicity induced by VHHFL-PS-ELPDB micelles in A431 and E98 cells. (A) Relative cell viability after incubation and illumination
with either 7D12FL-PS-ELPDB micelles, Fc5FL-PS-ELPDB micelles, or 7D12PS control. (B) Relative cell viability after incubation without illumination
with either 7D12FL-PS-ELPDB micelles or Fc5FL-PS-ELPDB micelles or 7D12PS control. Note the absence of dark toxicity. (C) Fluorescence
microscopy of DiD-labeled A431 (green) and DiO-labeled E98 (blue) (co)cultures that are incubated with propidium iodide (red) after incubation
with 30 nM 7D12-ELPDB or Fc5-ELPDB based PS-ELPDB particles or equimolar VHH 7D12PS and illumination. The scale bar denotes 100 μm.
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50% 7D12FL-ELPDB and 60% Fc5FL-ELPDB, respectively.
Above this ratio, uncontrolled aggregation resulted in micro-
meter-sized aggregates or coacervates (Figure 2D). The loss of
particle stability can be explained by a geometrical model.
Assuming a homogeneous sphere with a radius of 24 nm,
consisting of 214 monomers, each exposed monomer terminus
occupies a surface of 33.8 nm2 or a sphere with a radius of
approximately 2 nm. Since the radius of VHHs is around 2−3
nm,33 it is highly plausible that steric hindrance at high VHH-
ELPDB ratios occurs, leading to rearrangement and/or
aggregation.
Incorporation of 10% VHH-ELPDB resulted in well-deﬁned
micelles with physicochemical characteristics similar to ELPDB
micelles (Table 2, Figures 2C and S3). This percentage should
result in a display of approximately 20 VHH molecules per
micelle.
Since the LCST of ELPDB is concentration dependent, we
determined the critical micelle concentration (CMC) by
dynamic light scattering (DLS) and found that the CMC is
lower than 100 nM (Figure S4).
In order to mimic in vivo conditions we investigated the
eﬀect of the presence of human serum (HS) on the particle
properties. ELP micelles in HS were shown to be stable for at
least 2 h at 37 °C and, furthermore, could be reversibly
assembled in a temperature-dependent manner (Figure S5).
To separately follow the fate of VHH-ELPDB and ELPDB after
cellular uptake of composite micelles, we labeled VHH-ELPDB
with ﬂuorescein-5-maleimide (FL), yielding 7D12FL-ELPDB and
Fc5FL-ELPDB. ELPDB was labeled with Alexa647-N-hydrox-
ysuccinimide (NHS) ester or IRDye700DX (PS) via NHS
chemistry at the N-terminal amino group of ELPDB, yielding
Alexa647-ELPDB and PS-ELPDB, respectively (Table 1, Figure
S6).
FL-ﬂuorescence-based ﬂow cytometry, performed at 4 °C to
prevent self-assembly into micelles and internalization, showed
that monomeric 7D12FL-ELPDB, but not Fc5FL-ELPDB,
eﬀectively bound to EGFR-expressing A431 cells (Figure 3A),
demonstrating that the 7D12 moiety had retained its EGFR
aﬃnity. 7D12FL-ELPDB binding was slightly less than the
7D12FL control, indicating that the fusion to ELPDB may induce
some steric hindrance at low temperatures. No binding to the
EGFR-negative E98 cell line was observed for either 7D12FL-
ELPDB or Fc5FL-ELPDB. These experiments clearly illustrate
that the speciﬁcity of 7D12 remains unchanged in the context
of a fusion protein with ELPDB, and that ELPDB itself did not
show aspeciﬁc binding to the cell lines tested.
We next prepared micelles by heating a mixture of ELPDB,
Alexa647-ELPDB, and VHHFL-ELPDB (85:5:10) to 37 °C and
analyzed in vitro binding and uptake by measuring cell-
associated FL ﬂuorescence and Alexa647 ﬂuorescence in ﬂow
cytometry experiments. 7D12FL-Alexa647-ELPDB micelles
associated with A431 cells but not with EGFR-negative E98
cells (Figure 3B).
Incubation with composite 7D12FL-Alexa647-ELPDB micelles
resulted in 44% higher cell-associated FL ﬂuorescence relative
to the situation in which equal concentrations of (monomeric)
7D12FL were used, indicating a multivalency and avidity eﬀect
of 7D12FL induced by particle formation. Of note, incubation of
A431 with 7D12FL-Alexa647-ELPDB micelles also resulted in
cell-associated Alexa647 ﬂuorescence (Figure 3B), and
ﬂuorescence microscopy revealed membranous and intra-
cellular colocalization of both Alexa647 and FL (Figure S7),
indicating that 7D12FL associated with the cells as part of intact
micelles. Fc5FL-Alexa647-ELPDB micelles showed little back-
ground association with A431 cells. Altogether, these data show
that composite 7D12FL-Alexa647-ELPDB micelles that target
tumor cells in an EGFR-speciﬁc manner can be created.
Unfortunately, 7D12 binds to EGFR only in a cell context.34
Since the VHH is internalized upon EGFR binding at 37 °C, it
is diﬃcult to quantitatively compare avidity eﬀects of 7D12FL in
micellar or monomeric form, because at 37 °C results will
always be biased by internalization eﬀects. Future studies with
other VHH-ELP constructs that can be used in cell-free systems
may provide important answers on the subject of avidity.
In an eﬀort to determine the CMC of the functionalized
particles in vitro, we varied the concentration of all
components, maintaining the same ratios. As shown in Figure
3C, 7D12-induced binding and uptake of Alexa647-ELPDB
occurred at concentrations as low as 160 nM (VHH
concentration of 16 nM), showing the presence of cofunction-
alized micelles and agreeing with results obtained by DLS.
Using lower ELPDB concentrations for more accurate
determination of the CMC was not feasible due to insuﬃcient
ﬂuorophore signal-to-noise ratio. For a more accurate
determination in vitro, we used the photodynamic therapy
assay as described below.
To test whether EGFR-targeting ELPDB-based micelles can
be used in a therapeutic manner, we prepared 7D12FL-ELPDB
micelles containing the photosensitizer IRDye700DX, con-
jugated to ELPDB (PS-ELPDB). To achieve maximum drug
loading while maintaining suﬃcient targeting capacity, we
prepared micelles containing 2% VHHFL-ELPDB and 98% PS-
ELPDB. Cell-killing eﬃciency of these micelles was compared to
cell killing by monomeric 7D12, directly conjugated with
IRDye700DX (7D12PS). A431 or E98 cells were incubated with
7D12FL-PS-micelles or equimolar amounts of 7D12PS prior to
illumination. 7D12FL-PS-ELPDB micelles actively killed A431
cells in a light-dependent and 7D12-speciﬁc manner with an
EC50 concentration of 82.7 pM compared to 121.5 pM for the
7D12PS control (Figure 4A). This indicates that micelles were
formed already at a VHH concentration as low as 82.7 pM,
corresponding to an ELPDB concentration of 4.1 nM. No
toxicity was observed toward E98 cells, proving that 7D12-
mediated binding and uptake is necessary for toxicity. Control
micelles composed of 2% Fc5FL-ELPDB and 98% PS-ELPDB
showed no light-dependent toxicity upon illumination of either
A431 or E98 cells. Importantly, no dark toxicity of either
particle was found (Figure 4B). The cell-killing eﬃciency of
7D12-ELPDB particles preincubated in human serum at 37 °C
for up to 4 h, was surprisingly increased compared to particles
diluted in DMEM/10%FCS (Figure S8), indicating that
particles are stable and therapeutically active in 100% serum.
The cell-speciﬁcity of the particles was further conﬁrmed by
coculturing DiO-labeled A431 (green) and DiD-labeled E98
(blue) cells and performing photoimmunotherapy as described
above. By staining dead cells with propidium iodide, it was
observed that only EGFR expressing A431 cells died (Figure
4C). Thus, targeted photoimmunotherapy with 7D12FL-PS-
ELPDB micelles is highly speciﬁc for target-expressing cells
without harming neighboring target-negative cells.
The used light dose of 60 J/cm2 is physiologically relevant;
clinical studies reported safe use of light doses up to 125 J/cm2
in, for example, nonsmall cell carcinoma in the lung and cervical
cancer.35 Still, the penetration depth of near-infrared light is
below 1 cm, and therefore this treatment will often have to be
combined with surgery.
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Assuming Poisson distribution, 2% VHH-ELPDB are
suﬃcient to ensure that ∼98% of all particles contain at least
one targeting moiety. This leaves ample opportunities to
combine several targeting groups in one particle and to further
optimize their composition.
■ CONCLUSION
In conclusion, we have shown successful self-assembly of VHH-
ELPDB conjugates into micelles that can be used for targeted
photodynamic therapy in vitro and potentially in vivo. The 24
nm radii of these micelles are considered excellent for
nanomedicine; large enough to avoid rapid clearance from
the circulation, yet small enough to extravasate and penetrate
the intercellular space of tumors. The system allows
implementation of multiple VHHs to generate multitargeted
drug delivery nanoparticles. Spontaneous micelle formation
required concentrations as low as 4.1 nM. Further eﬀorts will
focus on validating the in vivo stability and activity of ELPDB
nanoparticles. Combining the system with therapeutic and
diagnostic molecules may result in an interesting theranostic
platform.
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